Study of HIV prevalence among key populations in Europe

A piece of the bigger picture: evidence on HIV prevalence among key populations in Europe
Simple or pooled HIV seroprevalencea among men who have sex with men, by European Union/European Economic Area country and the United Kingdom, 2009–2019 (n = 32 studies). Credit: DOI: 10.2807/1560-7917.ES.2021.26.47.2100044

Marking World AIDS Day on 1 December, Eurosurveillance has published an article that brings together evidence on HIV seroprevalence in five population groups affected by HIV in the countries of the European Union and European Economic Area (EU/EEA): men who have sex with men (MSM), people who inject drugs (PWID), people in prison, sex workers and transgender people.

Sex between men is the main HIV transmission mode (39% in 2019) among newly reported diagnoses in the EU/EEA overall while injecting drug use accounted for 4% of all new diagnoses. Over the years, many European HIV prevention and consequently have been targeted towards MSM and PWID in the attempt to address their higher risk for HIV and other sexually transmitted and blood-borne infections.

HIV in key populations: Lack of routine data

Alongside these two , prisoners, sex workers and have a similar risk due to structural, legal, social, economic, behavioral and biological factors. In addition, there is no standardized way of collecting and including information on risk factors such as sex work or imprisonment in national surveillance data for these groups, which leads to a gap in the understanding of HIV epidemiology in those key populations across Europe.

In their systematic literature review, Stengaard et al. pooled peer-reviewed studies published during 2009–2019 and identified 87 country- and population-specific studies from 23 countries for analysis. The resulting data were grouped by key population and presented in forest plots by country with simple or pooled (if two or more studies were identified) prevalence and 95% confidence intervals.

MSM and PWID combined both the highest number of studies and the largest identified variation in HIV prevalence, ranging from 2.4–29.0% (19 countries) for MSM and from 0.0–59.5% (13 countries) for PWID.

Among prisoner (nine countries) populations, prevalence ranged from 0.0–15.6% based on available data from the literature, and in sex workers prevalence ranged between 1.1–8.5% (five countries). For HIV prevalence in transgender people, data was retrieved from only one country, indicating a prevalence of 10.9%. Individuals belonging to several key population groups showed higher HIV prevalence.

Closing a knowledge gap

Given that more studies about MSM and PWID were identified, the authors outline a knowledge gap regarding HIV prevalence in the other groups for many countries in Europe, with for example extremely limited published data on HIV prevalence among transgender people.

Stengaard et al. conclude that "Our results complement other available data sources on the epidemiology of HIV in Europe, particularly HIV case surveillance data published at the European and national level, by providing additional information about HIV prevalence in key populations that are not covered as part of most routine case surveillance data (notably concerning prisoners, sex workers, and transgender people)."

More information: Annemarie Rinder Stengaard et al, HIV seroprevalence in five key populations in Europe: a systematic literature review, 2009 to 2019, Eurosurveillance (2021). DOI: 10.2807/1560-7917.ES.2021.26.47.2100044

Provided by European Centre for Disease Prevention and Control (ECDC)
Citation: Study of HIV prevalence among key populations in Europe (2021, November 26) retrieved 19 April 2024 from https://medicalxpress.com/news/2021-11-hiv-prevalence-key-populations-europe.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Prevalence of primary sclerosing cholangitis in inflammatory bowel disease explored

19 shares

Feedback to editors